Regulatory authority submissions

Submission coordination shaped by pathway and jurisdiction.

EU/EEA, UK and US applications have distinct routes, terminology and lifecycle expectations.

EU & EEA

For medicinal-product trials under the Clinical Trials Regulation, CTIS is the entry point for one or more EU/EEA Member States.

CTIS and EU submissions →

United Kingdom

The UK has its own legislation and MHRA guidance; it is outside the CTIS route.

UK submissions →

United States

US investigational new drug programmes follow FDA requirements, with registration duties potentially applying.

US submissions →

Clear ownership from dossier plan to lifecycle follow-up.

Application planning

Countries, pathway, core documents, dependencies and timetable.

Document coordination

Inputs, versions, translations and submission-ready approvals.

Lifecycle follow-up

Questions, decisions, amendments and agreed post-submission actions.